{'fraction_non_alphanumeric': 0.018085106382978722, 'fraction_numerical': 0.002127659574468085, 'mean_word_length': 5.76978417266187, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Understanding the pharmaceutical approach to pain management in canine osteoarthritis

Canine osteoarthritis was recently reclassified as a welfare concern by the Veterinary Companion Animal Surveillance System (VetCompass), an initiative run by the Royal College of Veterinary Surgeons, focused on improving companion animal health. This condition is a common cause for consultation in first opinion practice, with an estimated 35% of the canine population being affected. Chronic pain is complex and a multimodal approach is best for management, which includes pharmaceuticals employed in a methodical manner. This article provides an overview of the types of pain associated with canine osteoarthritis, as well as how to recognise them. Making reference to hypothetical cases, the appropriate pharmaceutical management is described. Further management strategies, as part of a multimodal approach, are summarised to ensure best practice.